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Abstract
Background: The aim of this study was to evaluate atrial humoral function and renal
function after pacemaker implantation due to atrioventricular conduction disturbances.
We analyzed blood atrial natriuretic peptide (ANP) concentration and basic parameters of
renal function within 1 month of implantation of VVI and DDD pacemakers. We evaluated
correlations between blood ANP values and basic renal function parameters.
Methods: We studied two groups of patients with atrioventricular (AV) conduction distur-
bances: second-degree AV block and third-degree AV block. Group I comprised 20 patients
aged 71–90 years (median 77.5 ± 5.9 years) in whom permanent VVI pacing was applied, and
group II consisted of 20 subjects aged 49–81 years (median 68.9 ± 11.9 years) in whom DDD/
/VDD pacemakers were implanted. The control group consisted of 15 healthy volunteers aged
58–80 years (median 72.7 ± 2.8 years). Plasma concentration of ANP was determined by
radioimmunoassay. The parameters of renal function we analyzed with Jaffe’s colorimetric
and kinetic test.
Results: Patients in group I showed a significant decrease in blood concentration of ANP
from 168.1 ± 81.9 pg/1000 mL to 118.0 ± 61.1 pg/1000 mL (p < 0.01) 7 days after implanta-
tion. At 30 days, ANP was 121.4 ± 71.9 pg/1000 mL. In group II, plasma concentration of
ANP decreased significantly from 134.9 ± 8.1 pg/1000 mL to 104.9 ± 6.1 pg/1000 mL (p < 0.01)
7 days after implantation and to 110.8 ± 53.3 pg/1000 mL at 30 days. Patients in group I had
elevated, albeit insignificantly, clearance of creatinine to 76.1 ± 17.8 ml/min at 7 days
(p > 0.05) which increased significantly to 85.0 ± 17.9 ml/min at 30 days. In group II, clearance
of creatinine increased insignificantly to 84.6 ± 13.2 ml/min (p < 0.05) at 7 days and was
significantly elevated to 96.9 ± 18.2 ml/min (p < 0.05) at 30 days. In group I, plasma concentra-
tion of creatinine decreased significantly (p < 0.05) to 1.15 ± 0.30 mg/dl at 7 days and to 1.01 ±
± 0.21 mg/dl at 30 days. In group II, there was a significant decrease (p < 0.05) to 1.15 ± 0.24 mg/dl
at 7 days and to 1.08 ± 0.27 mg/dl at 30 days. There was a positive correlation between
creatinine clearance and plasma ANP concentration in groups I and II (r = 0.301; p < 0.05).
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Conclusions: In patients with a pacemaker implanted due to atrioventricular disturbances,
blood concentration of ANP was decreased. Renal function was improved after pacemaker
implantation. (Cardiol J 2007; 14: 568–572)
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Introduction
Natriuretic peptides play a very important role
in the regulation of the cardiovascular system [1].
The first reports on endocrine function of the heart
date back to 1956, when Kish [2] described os-
mophilic granules in the atrial muscle cells of guin-
ea pigs. Later in 1981, de Bold et al. [3] observed
significant renal natriuretic excretion after intrave-
nous injection of atrial myocardial extract in rats.
Subsequent studies demonstrated the existence of
the natriuretic peptide family. The group includes,
generally: atrial natriuretic peptide (ANP), brain
natriuretic peptide (BNP), C — type natriuretic
peptide (CNP) and urodilatin [4, 5]. Te increased
stretch of the atrial muscle is the main mechanism
stimulating ANP release [6]. This is according to
Laplace’s law which says that the cavity wall ten-
sion depends on its dimension and the pressure
gradient across the wall. Therefore atrial pressure
elevation results in increased atrial stretch and in-
creased ANP secretion [7]. Animal experiments
showed that atrial and ventricular rates are inde-
pendent factors stimulating ANP secretion [8].
It was emphasized that mechanical stretch of atrial
cardiomyocytes can also influence ANP release.
Atrial secretion of natriuretic peptides proves
that they have a double role to play: mechanical and
endocrine [9].
In renal failure, elevated concentration of natri-
uretic peptides causes intense sodium secretion by
suppressing tubular sodium reabsorption [10].
Arterial hypertension, ischemic heart disease,
pericarditis is the most common cardiovascular dis-
ease coexisting with renal failure [11, 12]. On the
other hand, in chronic cardiovascular diseases such
as hypertension, ischemic heart disease or heart
failure, renal function parameters are increased. In
patients qualified for permanent pacing, changes in
levels of renal function parameters are possible
before, during and after longer procedures. The above
considerations inspired us to evaluate blood ANP
concentration and renal function within one month
of permanent pacemaker implantation. We also an-
alyzed the correlations between blood ANP values
and renal function parameters after implantation.
Methods
The study group comprised 55 patients with-
out clinical symptoms of renal failure, with sinus
heart rate, including 40 patients with II and III de-
gree atrioventricular (AV) conduction disturbances.
Group I consisted of 20 patients aged 71–90 years,
mean age 77.5 ± 5.9 years, with VVI pacemakers
implanted due to AV conduction disturbances.
Group II comprised 20 patients aged 49–81 years
old, mean age 68.9 ± 11.9 years, with DDD or VDD
systems. Group III, the control group, included
15 healthy volunteers, aged 58–80 years old, mean
age 72.6 ± 2.8 years.
We examined three groups of patients. Blood
samples were drawn for the determination of plas-
ma aANP before, 7 days and 30 days after pacemak-
er implantation, and only once in the control group.
aANP concentration of the blood was measured by
double-antibody radioimmunoassay kit (Human
aANP-RIA system RPA 512, Amersham) [13].
Creatinine clearance was analyzed with Jaffe’s
calorimetric and kinetic test. Creatinine, when
treated with picric acid in alkaline solution, forms
a coloured complex. Increase in absorption was
measured at 500 nm, which is proportional to creat-
inine concentration in material. We analyzed sam-
ples of plasma and urine from 24-hour urine collec-
tion. Reference values for daily creatinine excretion
were 1.0–2.5 g/24 h, and for creatinine clearance
75–110 ml/min. We used Technicon Ra 1000 auto-
mated analyzer for measurements [14].
Results
In patients before pacemaker implantation,
blood concentration of ANP achieved its highest
level in group I (168.6 ± 81.9 pg/1000 mL) and was
statistically higher (p < 0.05) compared to the control
group III (47.6 ± 12.9 pg/1000 mL). In group II, ANP
plasma level was 134.9 ± 83.1 pg/1000 mL (Fig. 1).
In patients with an implanted pacemaker in group I,
blood concentration of ANP decreased significant-
ly (p < 0.05) to 118.0 ± 61.1 pg/1000 mL 7 days af-
ter implantation and to 121.4 ± 71.9 pg/1000 mL at
30 days (Fig. 1). In group II, ANP levels decreased
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significantly (p < 0.05) to 105.0 ± 57.1 pg/1000 mL
at 7 days and to 110.8 ± 53.3 pg/1000 mL at 30 days
after pacemaker implantation (Fig. 1).
In patients before pacemaker implantation,
urine creatinine clearance based on measurement
of 24-hour urine reached its peak value in the control
group III (96.4 ± 35.8 ml/min) and was significantly
higher (p < 0.05) than in group I (72.1 ± 19.3 ml/
/min) and group II (82.3 ± 15.9 ml/min) (Fig. 2).
After pacemaker implantation, in group I, cre-
atinine clearance increased significantly (p < 0.05)
to 76.1 ± 17.8 ml/min at 7 days and to 85.0 ±
± 17.9 ml/min at 30 days after the procedure (Fig. 2).
In group II, creatinine clearance increased signifi-
cantly (p < 0.05) to 84.6 ± 13.2 ml/min at 7 days
and to 96.9 ± 18.2 ml/min at 30 days after implan-
tation (Fig. 2).
Creatinine concentrations in patients before
pacemaker implantation reached the level of 1.19 ±
± 0.43 mg/1000 mL in group I, which was signifi-
cantly higher (p < 0.05) compared to the control
group III (0.91 ± 0.17 mg/1000 mL). In group II,
before pacemaker implantation, the level of creati-
nine in blood increased to 1.21 ± 0.24 mg/1000 mL
being also statistically higher in comparison to the
control group (Fig. 3).
Figure 1. Plasma concentration of atriall natriuretic peptide; P — control group, I — VVI group before pacing,
II — DDD/VDD group before pacing, IA — VVI group 7 days after implantation, IB — VVI group 30 days after
implantation, IIA — DDD/VDD group 7 days after implantation, IIB — DDD/VDD group 30 days after implantation.
Figure 2. Creatinine clearance level; P — control group, I — VVI group before pacing, II — DDD/VDD group before
pacing, IA — VVI group 7 days after implantation, IB — VVI group 30 days after implantation, IIA — DDD/VDD group
7 days after implantation, IIB — DDD/VDD group 30 days after implantation.
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In group I, in patients with a permanent pace-
maker, blood creatinine concentration decreased to
1.15 ± 0.30 mg/1000 mL 7 days after the procedure
and to 1.01 ± 0.21 mg/1000 mL 30 days after im-
plantation, which was significantly lower (p < 0.05)
than blood creatinine levels in this group before
implantation of the pacemaker (Fig. 3). In group II,
in patients after implantation of the pacemaker, cre-
atinine concentration in blood samples decreased
after 7 days to 1.15 ± 0.24 mg/1000 mL and at
30 days to 1.08 ± 0.27 mg/1000 mL (Fig. 3).
Moreover, we observed a positive correlation
between plasma ANP and the increase in creatinine
clearance in groups I and II. This correlation was
found to be r = 0.301 (p < 0.05).
Discussion
All data obtained from patients qualified for
permanent pacemaker implantation indicate an in-
crease in atrial natriuretic peptide secretion. Com-
pared to the control group, blood ANP levels were
higher in both groups of patients.
At follow-up, ANP levels decreased in patients
with VVI mode pacemakers. Seven days after im-
plantation, ANP reached its mean and at 30 days,
its lowest value.
In patients after implantation of DDD/VDD
mode pacemakers, ANP blood concentration de-
creased during follow-up. The lowest value was
attained 7 days after the procedure and increased
slightly after 30 days.
In patients with VVI mode pacemakers com-
pared to the group with DDD/VDD pacemakers,
initial blood concentration of ANP was higher.
We also noticed higher dynamics of blood ANP de-
crease after the implantation in this group of patients,
with the lowest value at 7 days after the procedure.
Initially, in all patients before implantation of
permanent stimulating systems, renal function pa-
rameters (plasma creatinine concentration and cre-
atinine clearance) were significantly worse in com-
parison to the control group.
In both groups of patients, with VVI and with
DDD/VDD mode pacemakers, during 30-day follow-up,
there was a significant improvement of renal func-
tion expressed as increased creatinine clearance
and lower blood creatinine concentration. Chang-
es in basic, measurable renal function parameters
in patients with different stimulating system
modes are strongly dependent on renal activity of
natriuretic peptides. Natriuretic peptides affecting
kidney function increase glomerular filtration and
inhibit sodium reabsorption in the collecting tubuli
[15, 16].
Initial parameters of renal function during dif-
ferent types of stimulation have been investigated
in animal experiments and clinical trials. Yoneda et
al. [17] reported that during ventricular stimulation
in anesthetized dogs (pacing with increasing fre-
quencies 200–250 beats/min), no significant in-
crease of maximal urinary excretion of sodium was
observed. Seymour et al. [18] in their experimen-
tal studies in conscious, unstressed dogs observed
a decrease of renal filtration from 168 ± 19 ml/min
to 96 ± 9 ml/min and reduced sodium excretion
from 36 ± 5 to 10 ± 4 mEq/d, after rapid ventricular
pacing (260 beats/min). In subsequent experiments,
Figure 3. Blood creatinine concentration; P — control group, I — VVI group before pacing, II — DDD/VDD group
before pacing, IA — VVI group 7 days after implantation, IB — VVI group 30 days after implantation, IIA — DDD/VDD
group 7 days after implantation, IIB — DDD/VDD group 30 days after implantation.
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Williams et al. [19] observed that rapid ventricular
pacing produced a fall in both plasma vasopressin
and plasma renin activity, and a rise in urine flow
rate associated with an increase in free water but
not sodium clearance.
Analysis of renal function parameters in the
three groups of patients revealed that creatinine
clearance increased, whereas plasma creatinine
concentration decreased, after implantation of
a permanent pacemaker.
In conclusion, in patients with permanent stim-
ulation, blood ANP levels decrease after the implan-
tation, but greater dynamics of this fall can be ob-
served in the group with ventricular mode pacemak-
ers. Therefore, pacemaker implantation in patients
with advanced atrioventricular conduction distur-
bances significantly influences the improvement of
selected renal function parameters. Numerous cor-
relations between ANP values and renal function
parameters confirm this fact.
Permanent pacemaker implantation in patients
with advanced atrioventricular conduction distur-
bances, apart from direct therapeutic improvement,
influences indices of long-term cardiovascular re-
covery. This is expressed as a decrease in ANP
blood concentration and improvement in basic pa-
rameters of renal function.
Conclusions
1. In patients with severe atrioventricular conduc-
tion disturbances and permanent pacing, plas-
ma ANP concentration decreases.
2. During follow-up, in patients after pacemaker
implantation, there are numerous correlations
between blood ANP levels and renal function
parameters. These correlations are found
mainly in patients with DDD/VDD mode.
3. In patients with advanced atrioventricular con-
duction disturbances, after pacemaker implan-
tation, there is permanent improvement of re-
nal function parameters.
4. Atrial natriuretic peptide can be used to moni-
tor changes in the cardiovascular system and
renal function after pacemaker implantation.
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